Wanbury Limited has announced that its Register of Members and Share Transfer Books will remain closed from September 18, 2026, to September 24, 2026, for its 38th Annual General Meeting.

The company disclosed the schedule in a regulatory filing dated August 31, 2026. The 38th AGM is scheduled to be held on Thursday, September 24, 2026, at 11:30 am through Video Conferencing or Other Audio Visual Means.

Book Closure Details

Pursuant to Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the books will remain closed on both days inclusive. This period determines the shareholders eligible to vote at the meeting.

Meeting Logistics

The notice of the AGM will be sent electronically to members whose names appear in the Register of Members or Register of Beneficial Owners as on August 21, 2026. Shareholders must have registered email addresses with the company or their respective depositories to receive the communication.

The notice is also available on the company website and the listing exchanges. Wanbury Limited has engaged Purva Sharegriya to facilitate remote e-voting for all resolutions set out in the AGM notice.

Voting Procedures

Members holding shares in physical mode or those without registered email addresses must obtain login credentials from the Share Transfer Agent. The process requires submitting specific details, including folio numbers, PAN cards, and Aadhar cards, via email or post.

Physical mode shareholders should contact Purva Sharegriya (India) Pvt. Ltd. at their registered office in Mumbai. Demat account holders must coordinate with their Depository Participants to update email records.

Wanbury Limited has secured regulatory approvals from key global health authorities, strengthening its position in the active pharmaceutical ingredient (API) market. The company received approval from the European Directorate for the Quality of Medicines and HealthCare (EDQM) for its Rivaroxaban API. Additionally, Wanbury obtained Drug Master File (DMF) clearances from the US Food and Drug Administration (USFDA) for two APIs: Paroxetine HCl and Metformin HCl.

The press release, issued on August 13, 2026, pursuant to Regulation 30 of SEBI LODR, highlights that these approvals are critical for expanding the company's addressable market. The EDQM approval enables Wanbury to meet customer demand in the European Union and other countries that accept the Certificate of Suitability to the European Pharmacopoeia Monograph (CEP). Meanwhile, the USFDA DMF clearances were received while Anda (Abbreviated New Drug Application) reviews are underway for multiple customers, facilitating supply chain integration for finished dosage form manufacturers in the United States.

Regulatory approvals at a glance

The three clearances span two of the most stringent pharmaceutical regulatory frameworks globally. The following table summarises the specific approvals received:

Significance of the approvals

Rivaroxaban is an anticoagulant used in the management of blood clotting disorders. Paroxetine HCl is an antidepressant, and Metformin HCl is widely prescribed for type 2 diabetes management. These therapeutic categories represent significant global markets with consistent demand.

EDQM approval is a prerequisite for marketing APIs in European Union member states, providing a streamlined pathway for regulatory compliance across the region. USFDA DMF clearances are a critical step in the supply chain, allowing generic drug manufacturers to reference Wanbury's API data in their own regulatory submissions. These approvals collectively expand Wanbury's regulatory credentials and potential revenue streams across major geographies.